Cita APA

Pal, S., Somford, D. M., Grivas, P., Sridhar, S. S., Gupta, S., Bellmunt Molins, J., . . . Daneshmand, S. (2022). Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: The phase III PROOF 302 trial.

Citación estilo Chicago

Pal, Sumanta, et al. Targeting FGFR3 Alterations With Adjuvant Infigratinib in Invasive Urothelial Carcinoma: The Phase III PROOF 302 Trial. 2022.

Cita MLA

Pal, Sumanta, et al. Targeting FGFR3 Alterations With Adjuvant Infigratinib in Invasive Urothelial Carcinoma: The Phase III PROOF 302 Trial. 2022.